$OPSSF Opsens, the company, and the stock had been bucking the overall small-cap sector until the last quarter when there were some Covid-related issues. In my view, that represents an opportunity. Louis Laflamme, CEO of Opsens, has put together an excellent team, concurrently executing the company's vision. Earlier this week, Opsens received excellent news further bolstering that long-term vision.
OPSENS ANNOUNCES HEALTH CANADA APPROVAL FOR ITS NEW TAVR GUIDEWIRE
Source: Yahoo Finance
"For OpSens, Health Canada's approval is an important milestone on the path to the commercialization of the SavvyWire, which was specifically designed and developed to facilitate the procedure for transcatheter aortic valve replacement," commented Louis Laflamme, President, and CEO of OpSens. "The introduction of a next-generation guidewire with the ability to deliver a prosthetic valve and designed for rapid-pacing while allowing continuous measurement of hemodynamic pressure during the procedure is considered a significant benefit as the number of TAVR procedures is rapidly growing. We are prepared to initiate a phased commercialization in Canada over the coming months with a full launch expected toward the back half of 2022," concluded Mr. Laflamme.
Louis is excited about the future Opsens has in front of it, and he believes that patience will ultimately prevail for its stakeholders. Some additional near-term catalysts could garner more attention to the stock price and the value proposition the current share price holds.
I invite you to watch the interview and decide if Opsens is another "Hidden Gem!"
